

Use of Extracorporeal Support in Hemophagocytic Lymphohistiocytosis Secondary to Ehrlichiosis

Amy Cheng, MD,^a Feifei Williams, MD, FAAP,^{a,b} James Fortenberry, MD, FAAP, MCCM,^{a,b} Catherine Preissig, MD,^c Steven Salinas, MS,^d Pradip Kamat, MD, FAAP, MBA, FCCM^{a,b}

Ehrlichiosis, caused by transmission of *Ehrlichia chaffeensis* to humans through the bite of an infected lone star tick, can lead to secondary hemophagocytic lymphohistiocytosis (HLH), a life-threatening condition caused by uncontrolled activation of the cellular immune system. We describe a child with HLH secondary to ehrlichiosis who developed multiorgan failure and was successfully managed with extracorporeal membrane oxygenation (ECMO). A 9-year-old boy developed headaches, fever, and sore throat after suspected tick exposure. He presented with pancytopenia, elevated ferritin, and soluble interleukin-2 receptor levels, all consistent with HLH. Bone marrow biopsy revealed hemophagocytosis. Polymerase chain reaction was positive for *E chaffeensis*. He developed acute kidney injury, coagulation failure, hepatic insufficiency, and progressive respiratory failure requiring intubation. Due to refractory hypoxemia, he was cannulated for veno-venous ECMO. Continuous veno-venous hemofiltration was used to manage acute kidney injury and fluid overload. He received doxycycline and dexamethasone/etoposide for treatment of ehrlichiosis and HLH, respectively. Plasma exchange was used for thrombocytopenia-associated multiple organ failure. The patient was decannulated after 140 hours of ECMO and subsequently transferred for inpatient rehabilitation after extubation. Review of the Extracorporeal Life Support Organization Registry database identified 6 patients with tickborne diseases who received ECMO for organ support (survival in 3 of 6); ehrlichiosis was not reported in any of these cases. ECMO likely allowed a platform for stabilization and additional therapeutic interventions in this patient.

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease due to uncontrolled immune activation. HLH can be primary or secondary to an autoimmune process, immunodeficiency, malignancy, or infections. Isolated reports have described the development of HLH in patients with infection due to *Ehrlichia chaffeensis*, transmitted through the bite of an infected lone star tick.¹⁻³ The use of extracorporeal support to provide life-saving therapy in patients

with multiple organ failure (MOF) due to *E chaffeensis*-induced HLH has not been previously reported. We describe the successful use of veno-venous (VV) extracorporeal membrane oxygenation (ECMO) in a child with MOF due to HLH secondary to *E chaffeensis*.

CASE REPORT

A previously well 9-year-old boy developed headache, fever (39°F),

abstract

^aDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia; ^bDepartment of Critical Care Medicine, Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia; ^cDepartment of Critical Care Medicine, Children's Hospital Navicent Health, Macon, Georgia; and ^dUniversity of Georgia, Athens, Georgia

Dr Cheng drafted the initial manuscript and revised the manuscript; Drs Williams, Fortenberry, and Kamat critically reviewed and revised the manuscript; Dr Preissig reviewed and revised the manuscript and provided the pathology slides; Mr Salinas drafted the life cycle figure; and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

DOI: 10.1542/peds.2015-4176

Accepted for publication Jun 17, 2016

Address correspondence to Amy Cheng, MD, Pediatric Emergency Medicine, Emory University School of Medicine, 1645 Tullie Circle, Atlanta, GA 30329. E-mail: aychen5@emory.edu

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2016 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: No external funding.

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

To cite: Cheng A, Williams F, Fortenberry J, et al. Use of Extracorporeal Support in Hemophagocytic Lymphohistiocytosis Secondary to Ehrlichiosis. *Pediatrics*. 2016;138(4):e20154176

chills, and sore throat after suspected tick exposure. He was taken for emergency care 4 days after the onset of symptoms. On presentation, he was lethargic, with pallor and hepatomegaly. Laboratory evaluation revealed pancytopenia (white count $2.7 \times 10^9/L$, hemoglobin 8.2 gm/dL, platelet $68 \times 10^9/L$), transaminitis (aspartate transaminase 1304 mg/dL, and alanine transaminase 183 mg/dL), coagulopathy (prothrombin time 20.4 seconds), hyperferritinemia ($>40\,000$ ng/mL), elevated soluble interleukin-2 receptor (3022 pg/mL), high serum triglyceride (161 mg/dL), and decreased serum fibrinogen (138 mg/dL). Bone marrow biopsy revealed hemophagocytosis. He received intravenous (IV) vancomycin, ceftriaxone, and doxycycline for empirical antibiotic coverage. Polymerase chain reaction testing for *E chaffeensis* was positive. HLH was also suspected, as he met 5 of 8 criteria (Table 1), and dexamethasone was added for treatment. HLH genetic panel (perforin, Munc 13-4, and Munc 18-2) was subsequently negative, as were HIV-1 p24 antigen and HIV-1,2 antibodies. Polymerase chain reaction testing for adenovirus, cytomegalovirus, and Epstein-Barr virus were negative, and flow cytometry of peripheral blood did not reveal a clonal population suggestive of leukemia.

Despite aggressive support at an outlying facility, the patient required intubation for acute respiratory failure. He developed a severe coagulopathy, hepatic insufficiency, and acute kidney injury (AKI). On transfer to our quaternary care PICU, high-frequency oscillatory ventilation (HFOV) was initiated and quickly escalated to maximum settings. Inhaled nitric oxide was started due to profound hypoxemia. He was hypotensive and required an epinephrine infusion to maintain mean arterial pressure >60 mm Hg. Echocardiogram showed

TABLE 1 Diagnostic Criteria for HLH⁴

Fulfillment of 5 of the 8 criteria listed below:

1. Fever
2. Splenomegaly
3. Cytopenias (affecting at least 2 of 3 lineages in the peripheral blood):
 - Hemoglobin <9 g/100 mL (in infants <4 wk: hemoglobin <10 g/100 mL)
 - Platelets $<100 \times 10^9/L$
 - Neutrophils $<1 \times 10^9/L$
4. Hypertriglyceridemia (fasting, ≥ 265 mg/100 mL) and/or hypofibrinogenemia (≤ 150 mg/100 mL)
5. Hemophagocytosis in bone marrow, spleen, or lymph nodes
6. Low or absent natural killer cell activity
7. Ferritin ≥ 500 ng/mL
8. Soluble CD25 (soluble interleukin-2 receptor) >2400 U/mL (or per local reference laboratory)

a structurally normal heart with mildly decreased left ventricular ejection function of 45%. Due to the patient's rapid escalation of oxygenation index from 51 to 102 and his inability to maintain oxygen saturation $>88\%$, ECMO was recommended. He was cannulated for VV ECMO via the right internal jugular vein with a 27-French bicaval dual lumen cannula (Avalon Elite; Maquet Cardiovascular, Wayne, NJ). Echocardiogram was used to guide cannula position, with the arterial port flow jet directed toward the tricuspid valve.

ECMO flow was initiated on a centrifugal pump with a diffusion membrane oxygenator (Quadrox-iD; Maquet Cardiovascular) at 500 mL/min and increased to a maximum rate of 3300 mL/min (120 mL/kg/min) over 15 minutes. His blood oxygen saturation quickly improved after ECMO cannulation. Initially, the patient was placed on rest ventilator settings of pressure-control ventilation with peak inspiratory pressure 25, positive end expiratory pressure 10, pressure support 10, rate 10, fraction of inspired oxygen 30%. On day 4 of ECMO, the patient developed several episodes of profound hemochezia, totaled >1 L in volume, and required packed red blood cells (PRBCs), fresh-frozen plasma (FFP), and platelet transfusion. Given the profound gastrointestinal (GI) bleed, the patient was switched to HFOV for lung recruitment as an effort to

shorten the ECMO course in case it became necessary to discontinue ECMO emergently. HFOV was set to mean airway pressure 33, hertz 11, δP 76, fraction of inspired oxygen 40%. These settings resulted in marked improvement in chest radiograph and allowed for a successful capping trial. On day 5, the patient had a flexible bronchoscopy to remove secretions occluding subsegmental bronchi.

Profound coagulopathy and GI bleeding, which began before cannulation, remained problematic during his ECMO course. He required transfusions with PRBCs, FFP, platelets, and activated recombinant factor VII (2 mg) to stabilize bleeding before cannulation. Additionally, the patient received a loading dose and continuous infusion of IV aminocaproic acid as well as IV phytonadione. Heparin infusion (10 U/kg/h) was titrated to maintain acceptable activated clotting time levels (average 159 seconds). Heparin assays (anti-Xa level) were maintained at the lower therapeutic range due to bleeding (average level 0.29 U/mL). Furthermore, GI bleeding on ECMO day 4 required heparin infusion to be held for 9 hours until bleeding status improved. Hemochezia was treated with PRBCs, platelets, and FFP transfusions.

He received doxycycline for treatment of ehrlichiosis, along with dexamethasone and etoposide for HLH during his ECMO course.




FIGURE 1
Life cycle of *E. chaffeensis*.

In addition, he received plasma exchange therapy (centrifugation technique, Spectra Optia; CardianBCT, Lakewood, CO) for 5 days after meeting criteria for thrombocytopenia-associated MOF (ADAMTS 13 activity was decreased at 47%). Plasma exchange was performed with all FFP at 1.5 plasma volume on the first day and 1.0 plasma volume on the subsequent days. Continuous VV hemofiltration was initiated via the ECMO circuit due to AKI and generalized anasarca.

The patient had a successful decannulation after 140 hours of ECMO support. Continuous VV hemofiltration was stopped after ECMO decannulation. His serum ferritin and soluble interleukin-2 receptor levels continue to trend downward. His cardiac, hepatic dysfunction, and AKI completely resolved. The patient was successfully extubated on day 33 of hospital admission and transferred to the general care floor on day 38. He was discharged to the inpatient rehabilitation center on day 52. The patient is neurologically intact, and he continues to show clinical

improvement at subsequent follow-up visits.

To ascertain previous experience with use of ECMO in patients with tickborne diseases, *E. chaffeensis* infection, and HLH, we queried the database of the Extracorporeal Life Support Organization by using *International Classification of Diseases, Ninth Revision* codes. The Extracorporeal Life Support Organization registry is the world's largest database for pediatric and adult patients receiving extracorporeal support.⁵ Six patients were identified in the database with tickborne disease as the primary diagnosis requiring extracorporeal support. None of the patients had ehrlichiosis or coexistent HLH. Cases were reported from 1998 to 2012. Median patient age was 3.5 years. Venous-arterial ECMO was used in all the children, and 50% survived to discharge. Median duration of the ECMO run was 73 hours (range 14–148 hours).

DISCUSSION

HLH is a clinical syndrome caused by uncontrolled activation of the




FIGURE 2
Patient's peripheral blood smear: note cytoplasmic inclusions consistent with *E. chaffeensis* (Wright Giemsa Stain, 100x oil).

cellular immune system. This disease mainly involves macrophages and T-lymphocytes, resulting in upregulation of inflammatory cytokines. Although Epstein-Barr virus is the most common trigger for secondary HLH,^{6,7} other infectious agents, such as bacteria, fungi, *Mycobacterium*, protozoa, and rickettsial infections, have been documented in the literature.^{8,9} There are only a few documented pediatric cases of HLH secondary to ehrlichiosis.

E. chaffeensis is an obligate intracellular pathogen transmitted to humans through the bite of an infected lone star tick (*Amblyomma americanum*), often found in the southeastern and south-central part of the United States. The tick becomes infective after feeding on its primary reservoir host, the white-tailed deer (*Odocoileus virginianus*) (Fig 1). *E. chaffeensis* follows a lytic life cycle, and preferentially infects leukocytes once it enters a human's bloodstream (Fig 2). Typical incubation period is 1 to 2 weeks before symptom onset of fever, headache, fatigue, and muscle aches.

Ehrlichiosis should be considered in any pediatric patient with fevers after known or possible tick exposure. Severe disease due to ehrlichiosis is seen in children with underlying immunosuppressive conditions (chemotherapy, organ transplantation).¹⁰ Delay in early

recognition and initiation of treatment have been associated with worse outcomes.¹¹ Treatment should be considered as soon as possible without waiting for advanced laboratory testing, as case fatality rate is 1% to 2%.^{3,12}

The severity of our patient's presentation did not fit the typical paradigm for ehrlichiosis, particularly the degree of his acute respiratory failure and our inability to adequately provide oxygenation despite using maximum oscillator settings and inhaled nitric oxide. The development of secondary HLH was also unusual, with no previous report of these patients requiring ECMO support. From the onset, we provided aggressive interventions for the treatment of his multiorgan dysfunction. Initiation of VV ECMO stabilized the patient's respiratory status while allowing time for other therapeutic agents (corticosteroids, chemotherapy, and IV doxycycline) to treat HLH and ehrlichiosis. Various strategies were used to carefully balance coagulation while he was on ECMO support. Given the patient's severe GI bleeding, he was presumed to have excessive fibrinolysis. Aminocaproic acid was used to inhibit fibrinolysis, as it has been shown to decrease surgical bleeding in ECMO patients.¹³ Although activated factor VII has been noted to be associated with thrombosis in a few case series, more recent literature did not find an increased rate of thromboembolic complications in patients under ECMO support.¹⁴ Plasma exchange likely reversed MOF by decreasing circulating inflammatory cytokines and was useful in improving coagulopathy.

The aim of etoposide and dexamethasone is to suppress the inflammatory response and control cell proliferation. Although this patient had a positive outcome on this treatment regimen, previous study has shown that less

immunosuppressive and cytotoxic therapies, such as methylprednisone and IV immunoglobulin may have less toxic effects and better survival rates.¹⁵ Because there are currently no randomized controlled trials, more studies are warranted.

CONCLUSIONS

We report the first successful use of VV ECMO to support a child with severe MOF due to HLH secondary to ehrlichiosis. In our patient, ECMO allowed a platform for stabilization and time for additional therapeutic interventions.

ABBREVIATIONS

AKI: acute kidney injury
ECMO: extracorporeal membrane oxygenation
FFP: fresh-frozen plasma
GI: gastrointestinal
HFOV: high-frequency oscillatory ventilation
HLH: hemophagocytic lymphohistiocytosis
IV: intravenous
MOF: multiple organ failure
PRBCs: packed red blood cells
VV: veno-venous

REFERENCES

1. Burns S, Saylor R, Mian A. Hemophagocytic lymphohistiocytosis secondary to *Ehrlichia chaffeensis* infection: a case report. *J Pediatr Hematol Oncol*. 2010;32(4):e142–e143
2. Hanson D, Walter AW, Powell J. Ehrlichia-induced hemophagocytic lymphohistiocytosis in two children. *Pediatr Blood Cancer*. 2011;56(4):661–663
3. Vijayan V, Thambundit A, Sukumaran S. Hemophagocytic lymphohistiocytosis secondary to ehrlichiosis in a child. *Glin Pediatr (Phila)*. 2015;54(1):84–86
4. Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic

lymphohistiocytosis. *Pediatr Blood Cancer*. 2007;48(2):124–131

5. Paden ML, Rycus PT, Thiagarajan RR; ELSO Registry. Update and outcomes in extracorporeal life support. *Semin Perinatol*. 2014;38(2):65–70
6. Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. *Biol Blood Marrow Transplant*. 2010;16(suppl 1):S82–S89
7. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. *Eur J Pediatr*. 2007;166(2):95–109
8. Reiner AP, Spivak JL. Hematophagocytic histiocytosis. A report of 23 new patients and a review of the literature. *Medicine (Baltimore)*. 1988;67(6):369–388
9. Henter JI, Ehrnst A, Andersson J, Elinder G. Familial hemophagocytic lymphohistiocytosis and viral infections. *Acta Paediatr*. 1993;82(4):369–372
10. Dahlgren FS, Mandel EJ, Krebs JW, Massung RF, McQuiston JH. Increasing incidence of *Ehrlichia chaffeensis* and *Anaplasma phagocytophilum* in the United States, 2000–2007. *Am J Trop Med Hyg*. 2011;85(1):124–131
11. Hamburg BJ, Storch GA, Micek ST, Kollef MH. The importance of early treatment with doxycycline in human ehrlichiosis. *Medicine (Baltimore)*. 2008;87(2):53–60
12. Chapman AS, Bakken JS, Folk SM, et al; Tickborne Rickettsial Diseases Working Group; CDC. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichiosis, and anaplasmosis—United States: a practical guide for physicians and other health-care and public health professionals. *MMWR Recomm Rep*. 2006;55(RR-4):1–27
13. Downard CD, Betit P, Chang RW, Garza JJ, Arnold JH, Wilson JM. Impact of AMICAR on hemorrhagic complications of ECMO: a ten-year review. *J Pediatr Surg*. 2003;38(8):1212–1216
14. Niebler RA, Punzalan RC, Marchan M, Lankiewicz MW. Activated recombinant

factor VII for refractory bleeding during extracorporeal membrane oxygenation. *Pediatr Crit Care Med.* 2010;11(1):98–102

15. Demirkol D, Yildizdas D, Bayrakci B, et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple

organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? *Crit Care.* 2012;16(2):R52

**Use of Extracorporeal Support in Hemophagocytic Lymphohistiocytosis
Secondary to Ehrlichiosis**

Amy Cheng, Feifei Williams, James Fortenberry, Catherine Preissig, Steven Salinas
and Pradip Kamat

Pediatrics 2016;138;

DOI: 10.1542/peds.2015-4176 originally published online September 15, 2016;

**Updated Information &
Services**

including high resolution figures, can be found at:
<http://pediatrics.aappublications.org/content/138/4/e20154176>

References

This article cites 15 articles, 1 of which you can access for free at:
<http://pediatrics.aappublications.org/content/138/4/e20154176#BIBL>

Subspecialty Collections

This article, along with others on similar topics, appears in the
following collection(s):

Critical Care

http://www.aappublications.org/cgi/collection/critical_care_sub

Hematology/Oncology

http://www.aappublications.org/cgi/collection/hematology:oncology_sub

Blood Disorders

http://www.aappublications.org/cgi/collection/blood_disorders_sub

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or
in its entirety can be found online at:

<http://www.aappublications.org/site/misc/Permissions.xhtml>

Reprints

Information about ordering reprints can be found online:

<http://www.aappublications.org/site/misc/reprints.xhtml>

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Use of Extracorporeal Support in Hemophagocytic Lymphohistiocytosis Secondary to Ehrlichiosis

Amy Cheng, Feifei Williams, James Fortenberry, Catherine Preissig, Steven Salinas
and Pradip Kamat

Pediatrics 2016;138;

DOI: 10.1542/peds.2015-4176 originally published online September 15, 2016;

The online version of this article, along with updated information and services, is
located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/138/4/e20154176>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2016 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

